BUTAZOLIDIN
LOE ApproachingNDAORALCAPSULE
Approved
Jun 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BUTAZOLIDIN is an oral small-molecule drug approved by Novartis in 1997 as an NDA product. The specific indication and mechanism of action are not documented in available data, limiting characterization of its therapeutic role.
LOE Approaching
Loss of exclusivity is imminent; the brand team is likely in transition or contraction mode with reduced headcount and focus shifting to generic optimization or portfolio exits.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings signal minimal hiring or team expansion for BUTAZOLIDIN. Career growth is severely limited; most opportunities will involve defending market share against generics or managing portfolio wind-down.
Brand ManagerField Sales Representative
Worked on BUTAZOLIDIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.